Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial
- 30 April 2008
- journal article
- research article
- Published by Elsevier BV in The Breast
- Vol. 17 (2), 180-185
- https://doi.org/10.1016/j.breast.2007.09.002
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapyCancer Treatment Reviews, 2006
- Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic EraThe Oncologist, 2006
- Facts and Controversies in Systemic Treatment of Metastatic Breast CancerThe Oncologist, 2004
- Vinorelbine as a 96-Hour Continuous Infusion in Heavily Pretreated Patients with Metastatic Breast Cancer: A Cooperative Study by the GEICAM GroupClinical Breast Cancer, 2003
- Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinomaCancer, 2001
- Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.European Journal of Cancer, 2000
- Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or olderAnnals of Oncology, 1999
- Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.Journal of Clinical Oncology, 1997
- Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II studyCancer Chemotherapy and Pharmacology, 1996
- Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer ChemotherapyAmerican Journal of Clinical Oncology, 1995